Renal (Kidney) Cancer

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results... Continue Reading

FDA Approves Opdivo for Renal Cell Carcinoma (November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600... Continue Reading

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer (October 15, 2015)

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared... Continue Reading

FDA Grants Breakthrough Therapy Designation to LENVIMA™ for the Potential Treatment of Metastatic Renal Cell Carcinoma (August 3, 2015)

Eisai Inc. has announced that the U.S. Food and Drug Administration (FDA) granted LENVIMA™ (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation... Continue Reading

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival (July 29, 2015)

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase... Continue Reading

National Kidney Cancer Awareness Month on CancerConnect (March 6, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of kidney cancer educational programs for national kidney cancer awareness month. As the month of March brings kidney... Continue Reading

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading

First-Line Inlyta Active in Metastatic Kidney Cancer (December 11, 2013)

First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology. Each year in the United... Continue Reading

New Treatment Options for Advanced Renal Cell Carcinoma (October 8, 2012)

The results from three phase III trials shed new light on treatment options for patients with advanced renal cell carcinoma. The studies were presented at the ESMO 2012 Congress of the European Society... Continue Reading

Caregivers (September 25, 2012)

What is Caregiving and Who are Caregivers? Caregivers are individuals who provide care to chronically ill or disabled family members or friends. It is estimated that more than one quarter of the adult... Continue Reading

Men, Fertility, and Cancer (July 6, 2012)

Men who confront a cancer diagnosis before beginning or completing their families may have many questions about how cancer treatment will affect their ability to have children in the future. The good news... Continue Reading

PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase... Continue Reading

Coping with Taste Changes (June 4, 2012)

If you’re undergoing chemotherapy, biologic therapy, or radiation to the head or neck area, one of the side effects you may experience is a change in how things taste. While this may seem like a minor... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according... Continue Reading

Partial Nephrectomy is Associated with Improved Survival in Early Stage Kidney Cancer (April 27, 2012)

Patients with early stage kidney cancer who had only the tumor removed experienced better survival rates than those who had the entire kidney removed, according to the results of a study published in the... Continue Reading

Tivozanib Promising for Metastatic Renal Cell Carcinoma (April 23, 2012)

Tivozanib (AV-951) was well tolerated and improved median progression-free survival (PFS) in some patients with advanced renal cell carcinoma (RCC), according to the results of a phase II study published... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing... Continue Reading

Cancer Vaccines: Stimulating the Immune System to Attack Kidney Cancer (March 25, 2012)

With advances in personalized medicine, the look and feel of cancer treatment may change dramatically. What if, rather than receiving one-size-fits-all anticancer drugs, patients were treated with specially... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS